Ranjan Kumar Patel is at CPR.

Admin · 22 hrs

Inhalational insulin: Afrezza

• Afrezza (technosphere) is an inhalational insulin approved for treatment of only postprandial hyperglycemia
prior to meals (multiple dosing).
• For maintenance basal insulin is also given at loading dose along with afrezza.
• Absorption is rapid with peak plasma insulin level reaching within 15 minutes and then declines to baseline after
3 hours.
• Use and throw colour coded cartridges of afrezza are available with 4, 8 and 12 units of insulin. • Most common
side-effect is cough and few cases of lung cancer has also been seen in trials.
• It is contraindicated in smokers and patients of asthma and COPD.
#dr_ranjan